---
title: "Anthem Biosciences Ltd (ANTHEM) — Share Price, Financials & Analysis"
symbol: "ANTHEM"
company: "Anthem Biosciences Ltd"
canonical: "https://tapetide.com/stocks/ANTHEM"
isin: "INE0CZ201020"
nse_symbol: "ANTHEM"
bse_code: "544449"
sector: "Healthcare"
industry: "Biotechnology"
market_cap_cr: 53526.06
generated_at: "2026-09-13T18:46:46.862Z"
---

# Anthem Biosciences Ltd (ANTHEM)

Canonical page: https://tapetide.com/stocks/ANTHEM

## Company

- **NSE Symbol:** ANTHEM
- **BSE Code:** 544449
- **ISIN:** INE0CZ201020
- **Sector:** Healthcare
- **Industry:** Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-07-21
- **CEO:** Mr. Ajay Bhardwaj B.Tech., M.S
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** anthembio.com

## About

Incorporated in 2006, Anthem Biosciences 
Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]

## Latest Price

- **Price:** ₹940.9
- **Change:** -1.4 (-0.15%)
- **Open:** ₹938.1
- **Day High:** ₹952
- **Day Low:** ₹932.7
- **Previous Close:** ₹942.3
- **Volume:** 844305
- **As Of:** 2026-09-11T10:20:07+00:00

## Key Fundamentals

Observed at 2026-09-11T04:34:08.630094Z.

- **Market Cap:** ₹53526.06 Cr
- **Classification:** Midcap
- **P/E (reported):** 92.1
- **P/E (TTM):** 91.8
- **EPS (TTM):** ₹10.25
- **Book Value:** ₹54.01
- **Price to Book:** 17.43
- **Dividend Yield:** 0.21%
- **ROE:** 19.45%
- **ROCE:** 26.78%
- **Debt to Equity:** 0.02
- **Revenue (yearly):** ₹2280.1 Cr
- **Net Income:** ₹591.8 Cr
- **EBITDA:** ₹989.6 Cr
- **52-Week High:** ₹977.55
- **52-Week Low:** ₹579.15
- **RSI (14):** 63.53

## Tapetide Score

- **Score:** 53 / 100
- **Score date:** 2026-09-04
- **Archetype:** Priced for Perfection
- **What it means:** The business scores well but the multiple leaves little room for error. The debate here is about the price, not the company; small disappointments tend to cost more at rich valuations.
- **Pillar profile:** Quality: Good · Valuation: Expensive · Momentum: Rising
- **Percentile:** 61 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 85.23 | 9% |
| growth | 5.09 | 9% |
| momentum | 73.58 | 12% |
| ownership | 57.78 | 24% |
| quality | 78.38 | 22% |
| valuation | 23.73 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company is almost debt free.
- Company's working capital requirements have reduced from 118 days to 92.3 days

### Weaknesses

- Stock is trading at 17.4 times its book value
- Promoter holding has decreased over last quarter: -3.25%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 212.14% | 502.56% | 153.67% |
| ebitda margin growth | -45.05% | 10.74% | 13.2% | -9.51% |
| net income growth | -36.83% | 31.13% | 21% | 17% |
| revenue growth | -33.18% | 18.12% | 26% | 14% |
| roce | -48.01% | -0.41% | 13.28% | 28.88% |
| roe | -36.79% | 3.84% | 19.09% | -35.02% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 339 | 525 | 498 | 483 | 540 | 550 | 423 | 611 | 418 |
| Expenses | 218 | 330 | 338 | 288 | 349 | 332 | 266 | 344 | 268 |
| Operating Profit | 121 | 195 | 160 | 195 | 191 | 218 | 157 | 267 | 151 |
| OPM % | 36 | 37 | 32 | 40 | 35 | 40 | 37 | 44 | 36 |
| Other Income | 19 | 28 | 24 | 14 | 23 | 48 | 8 | 52 | 25 |
| Interest | 4 | 4 | 3 | 1 | 2 | 3 | 0 | 2 | 1 |
| Depreciation | 19 | 20 | 20 | 30 | 26 | 34 | 35 | 40 | 30 |
| Profit before tax | 118 | 200 | 161 | 178 | 186 | 230 | 130 | 278 | 145 |
| Tax % | 30 | 19 | 23 | 54 | 27 | 24 | 29 | 32 | 17 |
| Net Profit | 82 | 162 | 124 | 83 | 136 | 173 | 93 | 190 | 120 |
| EPS in Rs | 1.47 | 2.9 | 2.22 | 1.48 | 2.42 | 3.09 | 1.65 | 3.38 | 2.13 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 633 | 1103 | 1231 | 1057 | 1419 | 1845 | 2124 | 2002 |
| Expenses | 451 | 695 | 666 | 626 | 914 | 1173 | 1290 | 1209 |
| Operating Profit | 182 | 408 | 565 | 431 | 506 | 672 | 834 | 793 |
| OPM % | 29 | 37 | 46 | 41 | 36 | 36 | 39 | 40 |
| Other Income | 21 | 37 | 49 | 139 | 63 | 85 | 131 | 133 |
| Interest | 20 | 17 | 10 | 9 | 10 | 11 | 7 | 6 |
| Depreciation | 62 | 62 | 58 | 64 | 82 | 89 | 134 | 138 |
| Profit before tax | 121 | 366 | 546 | 497 | 477 | 657 | 824 | 783 |
| Tax % | 23 | 26 | 26 | 23 | 23 | 31 | 28 | — |
| Net Profit | 93 | 271 | 406 | 385 | 367 | 451 | 592 | 576 |
| EPS in Rs | 110.62 | 319.74 | 462.09 | 6.75 | 6.57 | 8.07 | 10.54 | 10.25 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 19 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 8 | 8 | 9 | 114 | 112 | 112 | 112 |
| Reserves | 413 | 693 | 1346 | 1627 | 1813 | 2298 | 2930 |
| Borrowings | 159 | 100 | 35 | 126 | 239 | 113 | 54 |
| Other Liabilities | 207 | 232 | 228 | 148 | 235 | 284 | 333 |
| Total Liabilities | 787 | 1034 | 1619 | 2014 | 2398 | 2808 | 3429 |
| Fixed Assets | 306 | 361 | 329 | 449 | 483 | 705 | 783 |
| CWIP | 50 | 19 | 154 | 164 | 345 | 297 | 264 |
| Investments | 99 | 209 | 273 | 499 | 472 | 433 | 1007 |
| Other Assets | 333 | 445 | 863 | 902 | 1099 | 1373 | 1374 |
| Total Assets | 787 | 1034 | 1619 | 2014 | 2398 | 2808 | 3429 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 166 | 278 | 333 | 306 | 140 | 271 | 844 |
| Cash from Investing Activity | -109 | -196 | -205 | -376 | -221 | -147 | -702 |
| Cash from Financing Activity | -48 | -63 | 181 | 64 | -77 | -136 | -40 |
| Net Cash Flow | 9 | 18 | 308 | -6 | -158 | -12 | 103 |
| Free Cash Flow | 119 | 159 | 307 | 112 | -156 | 12 | 637 |
| CFO/OP | 116 | 85 | 81 | 98 | 51 | 64 | 126 |

### Ratios

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 61 | 84 | 97 | 95 | 126 | 89 | 101 |
| Inventory Days | 186 | 29 | 52 | 139 | 129 | 167 | 56 |
| Days Payable | 87 | 50 | 50 | 77 | 61 | 54 | 34 |
| Cash Conversion Cycle | 160 | 63 | 99 | 156 | 193 | 202 | 124 |
| Working Capital Days | 20 | 27 | 75 | 112 | 128 | 134 | 92 |
| ROCE % | — | 55 | 51 | 28 | 24 | 28 | 30 |

## Shareholding Pattern

### Quarterly

| Category | Dec 2024 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- |
| Promoters | 77.23% | 74.69% | 74.69% | 74.68% | 71.42% |
| FIIs | 0% | 1.67% | 1.36% | 1.28% | 2.58% |
| DIIs | 0% | 7.22% | 7.6% | 11.55% | 13.48% |
| Government | 0% | 0% | 0% | 0% | 0% |
| Public | 0% | 9.61% | 9.6% | 9.38% | 9.42% |
| Others | 22.77% | 6.81% | 6.74% | 3.12% | 3.11% |
| No. of Shareholders | 16 | 217681 | 199492 | 180220 | 173273 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 6 / 1

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 935.43 | Buy |
| EMA (10) | 933.65 | Buy |
| SMA (20) | 913.85 | Buy |
| EMA (20) | 913.5 | Buy |
| SMA (50) | 845.09 | Buy |
| EMA (50) | 864.37 | Buy |
| SMA (100) | 808.64 | Buy |
| EMA (100) | 818.07 | Buy |
| SMA (200) | 733.57 | Buy |
| EMA (200) | 779.11 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 63 | Neutral |
| MACD (12,26,9) | 28.12 | Sell |
| Stochastic (14,3,3) | 66.89 | Neutral |
| ADX (14) | 42.6 | Buy |
| Williams %R (14) | -34.4 | Neutral |
| ATR (14) | 29.13 | High Volatility |
| ROC (12) | 1.93 | Buy |
| Stoch RSI (14) | 25.78 | Neutral |
| UO (7,14,28) | 41.51 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 8 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 8 analyst ratings, observed at 2026-09-11T04:34:10.856954+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-08 | [Settlement Of Upside Sharing Arrangement](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca5d9f0c-7edd-47ec-8b96-94ad84a19d28.pdf) |
| 2026-07-24 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b598d048-1013-4f82-bed0-88518f74c3ef.pdf) |
| 2026-07-22 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=60bdf180-b25e-429b-846f-08223ac71ca5.pdf) |
| 2026-07-22 | [Announcement Under](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6653d5bd-31ce-4a5d-94bd-29a8b7755a03.pdf) |
| 2026-07-21 | [Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday July 21 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=74c27957-ead0-4e7f-8dc6-a789058d2954.pdf) |
| 2026-07-21 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0e1a95b7-dbcc-491c-9ecd-e9700952f3df.pdf) |
| 2026-07-21 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d5cf28b6-a75a-4bf1-b288-a3ccc8b53374.pdf) |
| 2026-07-15 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1dc2797a-dd69-4b0f-9292-225dc919e1d1.pdf) |
| 2026-07-14 | [Board Meeting Intimation for Financial Results For Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=268cbe4c-46d9-4ab0-9b81-b330b1990b6d.pdf) |
| 2026-07-10 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4c76f866-44e4-4490-a6d8-100a92791138.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-07-27 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e75982f4-ce0c-4960-91d4-f99d4f30a48f.pdf) |
| 2026-05-22 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e763406b-06a2-475e-95c9-114c82a4108a.pdf) |
| 2026-02-09 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=51338f86-b191-4a62-a100-0cca33a3b3dc.pdf) |
| 2025-11-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c2e49a19-a719-4d38-8a83-28d377e4e844.pdf) |
| 2025-08-18 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6642b948-ce4f-437e-87fa-cc6b98e18b80.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-07-22 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f2f8a40-e000-4eb3-870b-cbb615291dad.pdf) |
| 2026-05-20 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=393f3b44-6016-422c-9348-b01a36788eaa.pdf) |
| 2026-02-05 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b58b6cb9-6257-4321-9e00-9cc232d5dc02.pdf) |
| 2025-11-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=95f391b1-406a-4214-8b74-730ccbc5768d.pdf) |
| 2025-08-14 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=03bfc7c8-35d9-44fa-add2-0f8b1999d9d9.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-21 | [Financial Results For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c93f3775-993c-4788-905c-dbe631194ac3.pdf) |
| 2026-05-19 | [Approval Of Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=84758a79-4e54-4c0b-85b2-a0227b013993.pdf) |
| 2026-02-05 | [Financial Results For The Quarter And Nine Months Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=877d0b85-d078-4156-a119-6ea72614b4a0.pdf) |
| 2025-11-08 | [Outcome Of The Board Meeting Held On Saturday November 08 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eb7bc415-18ef-4e73-9dd3-d86067a458b3.pdf) |
| 2025-08-13 | [Outcome Of Board Meeting Held On Wednesday August 13 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=58cd8e1b-c373-4759-9b9c-0b0bb305d59a.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-07-21 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a0e186de-aa3b-41b5-a8fb-7cea7b263a5d.pdf) |
| 2026-07-21 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4b54ba56-4be6-401d-8bc9-5ae10624c6a7.pdf) |
| 2026-05-19 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b9fd18a1-0037-4310-b2c2-25e124964ed5.pdf) |
| 2026-02-05 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1bb2c5d7-de77-42f2-8db1-ba1ea7daa022.pdf) |
| 2025-11-08 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6b25f96c-2dc4-4879-94d3-42e991e95d82.pdf) |
| 2025-08-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3702497f-5880-4170-b1c1-c52828d3c96f.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c2e49a19-a719-4d38-8a83-28d377e4e844.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ea39e12f-cd9e-4ee7-8104-4c8b6a6b34ce.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/48bdf40f-f558-438d-96c9-3206b57c3bc5.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5b7c5a16-3471-4932-a4c0-8f5ab29ef970.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b885104f-c5fc-4c36-898d-f4fd9e7d1fab.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e763406b-06a2-475e-95c9-114c82a4108a.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/e763406b-06a2-475e-95c9-114c82a4108a.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/b9fd18a1-0037-4310-b2c2-25e124964ed5.pdf) |
| May 2022 | [Concall - May 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/233dd6f0-bae1-4a8f-bb7c-0b68950be365.pdf) |
| May 2022 | [Concall - May 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1d3d9594-3217-4860-aab2-a89d8198f7cd.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Board approved SR Batliboi as statutory auditor for 5 years and an upside-sharing payout of INR 1,276.83 million. | [Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s 9h - Board approved SR Batliboi as statutory auditor for 5 years and an upside-sharing payout of INR 1,276.83 million.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/4734d9e1-fe50-4e15-aeb1-96409adddf37.pdf) |
| 9 Feb - Investor Presentation for Results Earnings Call for Quarter and Nine Months ended on December 31, 2025 is enclosed herewith. Kindly take the same on record. | [Announcement under Regulation 30 (LODR)-Investor Presentation 9 Feb - Investor Presentation for Results Earnings Call for Quarter and Nine Months ended on December 31, 2025 is enclosed herewith. Kindly take the same on record.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f43b1341-6a7f-425c-80a9-4b8b6887590c.pdf) |
| 6 Feb - Newspaper Publication of Financial Results for the quarter and nine months ended December 31, 2025 | [Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Feb - Newspaper Publication of Financial Results for the quarter and nine months ended December 31, 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/865d525f-8943-4387-b6e2-bfa20b7bd9f8.pdf) |
| 6 Apr - Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended Marcg 31, 2026 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr - Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended Marcg 31, 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a573855d-4135-47a9-b79e-dd32ace81c89.pdf) |
| 5 Feb - Q3 and 9MFY26 results: 9MF revenue 15,134 Mn; EBITDA 6,712 Mn; PAT 4,020 Mn. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) 5 Feb - Q3 and 9MFY26 results: 9MF revenue 15,134 Mn; EBITDA 6,712 Mn; PAT 4,020 Mn.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/528b9f75-eb20-473a-ba02-d9597f12d6e5.pdf) |
| 5 Feb - Audio of earnings call for quarter and nine months ended Dec 31, 2025 published Feb 05, 2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 5 Feb - Audio of earnings call for quarter and nine months ended Dec 31, 2025 published Feb 05, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b58b6cb9-6257-4321-9e00-9cc232d5dc02.pdf) |
| 30 Apr - Anthem Biosciences says it is not a Large Corporate; outstanding borrowing was INR 2.96 crore. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Anthem Biosciences says it is not a Large Corporate; outstanding borrowing was INR 2.96 crore.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e7c3a4fe-14af-49e9-8a2d-07835d7e70c7.pdf) |
| 30 Apr - Anthem Biosciences says it is not a Large Corporate; outstanding borrowing was INR 2.96 crore. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Anthem Biosciences says it is not a Large Corporate; outstanding borrowing was INR 2.96 crore.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/e7c3a4fe-14af-49e9-8a2d-07835d7e70c7.pdf) |
| 23 Feb - First Amendment allows conversion of additional Rs 275 crore loan into Neoanthem equity; total sanction Rs 550 crore. | [Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 (SEBI LODR Regulations) 23 Feb - First Amendment allows conversion of additional Rs 275 crore loan into Neoanthem equity; total sanction Rs 550 crore.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/182e98e0-2e09-4c46-aca1-b3948efa61d3.pdf) |
| 22 Apr - Board approved SR Batliboi as statutory auditor for 5 years and an upside-sharing payout of INR 1,276.83 million. | [Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s 22 Apr - Board approved SR Batliboi as statutory auditor for 5 years and an upside-sharing payout of INR 1,276.83 million.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4734d9e1-fe50-4e15-aeb1-96409adddf37.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2022 from nse](https://archives.nseindia.com/annual_reports/AR_20786_SUPRIYA_2021_2022_23082022134729_08232022140002.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2acb789e-8958-4c5d-8131-d0677177f399.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ce151741-396c-411a-8399-f36911dcf9a7.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/04140113-39f5-4d78-93ac-9f3288a63bae.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/543434/74546543434.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:46:46.862Z.